2011
Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13
Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal Of Child And Adolescent Psychopharmacology 2011, 21: 555-564. PMID: 22070180, PMCID: PMC3279715, DOI: 10.1089/cap.2010.0134.Peer-Reviewed Original ResearchConceptsMedication-free subjectsEpidermal growth factorHealthy controlsInflammatory markersIL-13IL-1 receptor antagonistGrowth factorSerum inflammatory markersChemoattractant protein-1Placebo groupClinical improvementBaseline visitIL-17Serum levelsCytokine concentrationsInflammatory moleculesSerum concentrationsClinical trialsHealthy subjectsIL-1Interleukin-13RisperidoneAltered levelsProtein 1Diagnosis of autism
2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors
2003
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60: 1130-1135. PMID: 12682319, DOI: 10.1212/01.wnl.0000055434.39968.67.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBody WeightChildDiagnostic Techniques, NeurologicalDopamine AntagonistsDose-Response Relationship, DrugDouble-Blind MethodErectile DysfunctionFemaleHeart Conduction SystemHumansMaleMiddle AgedPhobic DisordersRisperidoneSeverity of Illness IndexTicsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScalePlacebo-controlled trialTotal tic scoreTourette syndromeTic scoreYGTSS total tic scoreCardiac conduction timesSafety of risperidonePrimary outcome measureWeeks of treatmentDurability of efficacyTic Severity ScaleShort-term treatmentMedication-free subjectsPlacebo patientsMedication discontinuationRisperidone groupExtrapyramidal symptomsTic symptomsOutcome measuresDose reductionConduction timeSeverity ScaleTic severityBody weight
2000
Risperidone-Associated Weight Gain in Children and Adolescents: A Retrospective Chart Review
Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF. Risperidone-Associated Weight Gain in Children and Adolescents: A Retrospective Chart Review. Journal Of Child And Adolescent Psychopharmacology 2000, 10: 259-268. PMID: 11191686, DOI: 10.1089/cap.2000.10.259.Peer-Reviewed Original ResearchConceptsBody mass indexSignificant weight gainBaseline weightRisperidone useWeight gainStandardized z-scoresZ-scoreConcomitant medication useRisperidone-treated subjectsWeight changeRetrospective chart reviewSmall case seriesPsychiatric inpatient populationProportion of subjectsSubstantial weight gainRisperidone dosageNeuroleptic exposureChart reviewMedication useMonths of observationCase seriesMass indexInpatient populationWeight increaseTanner staging
1995
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. The Journal Of Clinical Psychiatry 1995, 56: 526-8. PMID: 7592506.Peer-Reviewed Original ResearchConceptsSerotonin uptake inhibitorObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleRisperidone additionOCD patientsComorbid chronic tic disorderPatients' Y-BOCS scoresRefractory obsessive-compulsive disorderOpen-label mannerLow-dose haloperidolSide effect profileWeeks of treatmentChronic tic disorderEffective treatment strategiesObsessive Compulsive ScaleSUI treatmentEffect profileNeuroleptic treatmentTardive dyskinesiaTypical neurolepticsModerate sedationReceptor antagonistTic disordersTreatment strategies